You are here

Approvals, Launches, and New Indications

First and Only Treatment Reduces Depressive Symptoms Within Days
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
For Locally Advanced or Metastatic Triple-Negative Type Only
Subcutaneous Extended-Release Injectable With Risperidone Now Available in the U.S.
Treatment Options Are Limited After Failure of First- and Second-line Therapies
Minimally Invasive Procedure Uses Radio Waves to Thwart Pain
Disease Occurs in 1 in 5,000 Male Births in the U.S.
Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Trial Demonstrated Significantly Improved Survival Rates
New Chemotherapy-Free Option for Treating CLL and SLL
New Design Offers More Reliable SQ Delivery of Diabetes Meds  
New Influenza Vaccine Option Could Streamline Immunization Efforts
Sole FDA-Approved Test for Sexually Transmitted Infection
Herceptin Biosimilar Indicated for HER2-Overexpressing Breast Cancer, Metastatic Breast Cancer, and Metastatic Gastric Cancer
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Potential Life-Saving Device Can be Implanted in 2-LB Babies
New Therapy for Patients With HCC Who Previously Received Nexavar
Less Burdensome Therapy for Patients With Paroxysmal Nocturnal Hemoglobinuria
Drug Expected to Launch in 2019, Offering Hope to 35 Million U.S. Adults
New Antifungal Has Increased Bioavailability and Reduced Variability
New Biosimilar Provides Broader Treatment Options for Patients
Argos Device Could Reduce Cost and Amount of Work for CO Monitoring
Prescription App Can Serve As Training, Monitoring, and Reminder Tool
Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma